ARTICLE | Company News
AstraZeneca, Center for Drug Design and Discovery (CD3), Flanders Institute for Biotechnology (VIB) deal
February 10, 2014 8:00 AM UTC
AstraZeneca received exclusive, worldwide rights to develop and commercialize small molecule mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors from life science resea...